SPARC issues warrants worth Rs 1,200 crore to promoter Dilip Shanghvi, others

Published On 2021-05-14 07:01 GMT   |   Update On 2021-05-14 07:01 GMT

New Delhi: Sun Pharma Advanced Research Company (SPARC) plans to raise up to Rs 1,200 crore by way of issuing warrants to the company''s promoter Dilip Shanghvi and other entities.The proposal was approved by the company''s board during its meeting held on Wednesday, according to a regulatory filing.As per the filing, the board considered and approved issuing "up to 6,74,70,203 warrants...

Login or Register to read the full article

New Delhi: Sun Pharma Advanced Research Company (SPARC) plans to raise up to Rs 1,200 crore by way of issuing warrants to the company''s promoter Dilip Shanghvi and other entities.

The proposal was approved by the company''s board during its meeting held on Wednesday, according to a regulatory filing.

As per the filing, the board considered and approved issuing "up to 6,74,70,203 warrants each convertible into, or exchangeable for, one equity share within the period of 18 months at a price of Rs 178 each" to Dilip Shantilal Shanghvi, promoter of the company and to certain other non-promoter group persons.

These warrants -- aggregating up to Rs 12,00,96,96,134 -- would be allotted by way of a preferential issue.

Upon issue of warrants, an amount equivalent to 25 per cent of the total issue size shall be called upfront from the proposed allottees, the filing said.


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News